Brukinsa (zanubrutinib) — CareFirst (Caremark)
Waldenstrom macroglobulinemia
Initial criteria
- Used as a single agent OR
- Used in combination with rituximab.
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months